The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...
PARIS, Aug. 5, 2025 /PRNewswire/ -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young...
L’Avenue Derm debuts in Manhattan with a one-month waitlist, redefining holistic dermatologic care. Members receive 7-day access to top dermatologists, yoga, nutrition, and tailored aesthetic treatments—seamlessly blending convenience and clinical excellence at every touchpoint.
The digital therapeutics market is anticipated to increase due to the growing global burden of chronic conditions such as diabetes, cardiovascular disorders, and obesity...
The digital therapeutics market is anticipated to increase due to the growing global burden of chronic conditions such as diabetes, cardiovascular disorders, and obesity...
ATLANTA, Aug. 1, 2025 /PRNewswire/ -- MiRus has received New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS) for...
Clinical Stage Biotechnology Company Uses Patient Immune System to "Seek and Destroy" Cancer and Metastasis
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Res Nova Biologics,...
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data
PITTSBURGH, Aug. 1, 2025 /PRNewswire/...
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company’s aprevo® personalized interbody implants.
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025.
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...